Phase 2 Study of AG 013736 as Second-Line Treatment in Patients With Metastatic Renal Cell Cancer.

Trial Profile

Phase 2 Study of AG 013736 as Second-Line Treatment in Patients With Metastatic Renal Cell Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2015

At a glance

  • Drugs Axitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Sep 2015 Results of effects of different degrees of renal impairment from one phase 3 and three phase 2 studies published in the Targeted Oncology.
    • 09 Nov 2012 New source identified and integrated: German Clinical Trials Register record (Extension trial DRKS00004112).
    • 19 Apr 2012 Actual patient number changed from 22 to 52 as reported by ClinicalTrials.gov (Extension trial: NCT01056263).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top